# Sacubitril + Valsartan

## Entresto 100mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                         |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OENTR                                                                                                                                                                                                                                                                                           |
| Indications        | Heart failure， chronic， Class II to IV                                                                                                                                                                                                                                                        |
| Dosing             | CHF adult， initial 100mg BID， maintain dose: 200mg BID after 2-4 weeks. ( if Entresto switch from ACEI， it must be separated at least 36 hr)                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                   |
| Contraindications  | ■Angioedema to prior ACE inhibitor or angiotensin II receptor blocker therapy ■Concomitant aliskiren use in diabetic patients ■Concomitant use of ACE inhibitors; do not administer within 36 hours of each other ■Hypersensitivity to sacubitril， valsartan， or any component of the product |
| Adverse Effects    | common ■Cardiovascular: Hypotension (18% ) ■Endocrine metabolic: Hyperkalemia (12% ) ■Neurologic: Dizziness (6% ) serious ■Renal: Renal failure (5% ) ■Other: Angioedema (0.5% )                                                                                                                |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                         |

